key: cord-0995650-b6x8kzcv
authors: Selarka, Lav; Sharma, Suktara; Saini, Dinesh; Sharma, Sanjay; Batra, Amit; Waghmare, Vishal T.; Dileep, Pratibha; Patel, Sanket; Shah, Monarch; Parikh, Tejas; Darji, Prakash; Patel, Amit; Goswami, Gaurav; Shah, Anand; Shah, Sandeep; Lathiya, Harsh; Shah, Moksha; Sharma, Pranita; Chopra, Surabhi; Gupta, Ankur; Jain, Neha; Khan, Erum; Sharma, Vijay K.; Sharma, Arvind K.; Chan, Amanda C. Y.; Ong, Jonathan J. Y.
title: Mucormycosis and COVID‐19: An epidemic within a pandemic in India
date: 2021-07-24
journal: Mycoses
DOI: 10.1111/myc.13353
sha: 698e953f8250b9fe73bd860e46b83f30bc2b4c1b
doc_id: 995650
cord_uid: b6x8kzcv

IMPORTANCE: Coronavirus disease (COVID‐19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis and outcomes for mucormycosis among patients with COVID‐19 infection. METHODS: This prospective, observational, multi‐centre study included 47 consecutive patients with mucormycosis, diagnosed during their course of COVID‐19 illness, between January 3 and March 27, 2021. Data regarding demography, underlying medical conditions, COVID‐19 illness and treatment were collected. Clinical presentations of mucormycosis, imaging and biochemical characteristics and outcome were recorded. RESULTS: Of the 2567 COVID‐19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycosis. Mean age was 55 ± 12.8years, and majority suffered from diabetes mellitus (n = 36, 76.6%). Most were not COVID‐19 vaccinated (n = 31, 66.0%) and majority (n = 43, 91.5%) had developed moderate‐to‐severe pneumonia, while 20 (42.6%) required invasive ventilation. All patients had received corticosteroids and broad‐spectrum antibiotics while most (n = 37, 78.7%) received at least one anti‐viral medication. Mean time elapsed from COVID‐19 diagnosis to mucormycosis was 12.1 ± 4.6days. Eleven (23.4%) subjects succumbed to their disease, mostly (n = 8, 72.7%) within 7 days of diagnosis. Among the patients who died, 10 (90.9%) had pre‐existing diabetes mellitus, only 2 (18.2%) had received just one vaccine dose and all developed moderate‐to‐severe pneumonia, requiring oxygen supplementation and mechanical ventilation. CONCLUSIONS: Mucormycosis can occur among COVID‐19 patients, especially with poor glycaemic control, widespread and injudicious use of corticosteroids and broad‐spectrum antibiotics, and invasive ventilation. Owing to the high mortality, high index of suspicion is required to ensure timely diagnosis and appropriate treatment in high‐risk populations.

Coronavirus disease 2019 , attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a global pandemic by the World Health Organisation (WHO) in March 2020. [1] [2] [3] [4] The pandemic continues to be an ongoing public health concern with more than 162 million cases recorded, and more than 3 million deaths globally. 5 At the time of writing, the Indian subcontinent ranked second, after the United States, with more than 24 million COVID-19 cases reported. 5 With the escalation of cases worldwide, a myriad of potential complications from COVID-19 are being increasingly appreciated, including the heightened vulnerability to secondary bacterial and fungal infections. [6] [7] [8] [9] The immune dysregulation associated with COVID-19 is further aggravated by concomitant medical conditions such as diabetes mellitus, and the widespread use of immunosuppressive agents and broad-spectrum antibiotics. In addition, COVID-19 patients are more susceptible to develop secondary infections if they have decompensated pulmonary functions or require invasive mechanical ventilation. 6 The rate of in-hospital secondary bacterial and fungal infection has been reported to be approximately 8%. 6, 10 Previous reports observed that fungal infections were more likely to develop during the more advanced stages of COVID-19 infection, 11 with substantially higher mortality among patients with a fungal co-infection. 6 Mucormycosis is known to affect immunocompromised patients especially those with diabetes mellitus, prolonged corticosteroid use, solid organ transplant recipients, neutropenia and haematological malignancies. 6, [12] [13] [14] It is an opportunistic infection leading to invasion of blood vessels by fungal hyphae, causing infarction and necrosis of a variety of end-organ host tissues. 13 Rhino-orbital infection with the mucorales species of fungus portends a poor prognosis with a mortality rate reaching 50%, even with appropriate treatment. 13 Since the start of COVID-19 pandemic, there has been a renewed interest about secondary fungal infections, and some case reports and small case series have been published. The Indian subcontinent has witnessed a sudden and alarming surge in the number of mucormycosis cases in patients of COVID-19. At the time of writing this paper, considerable number of cases of mucormycosis have been reported, making it a health problem of epidemic proportions. 6, 8, 9, [11] [12] [13] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Given that the current pandemic continues to be a significant public health issue globally, there needs to be a heightened awareness about mucormycosis among patients with COVID-19, since both conditions in combination may lead to significant morbidity and mortality.

We postulated that the use of systemic corticosteroids in the treatment of COVID-19, especially among patients with poorly controlled diabetes mellitus, increased the incidence of mucormycosis infection.

We present a series of 47 cases, by far the largest prospective case series to date, with the objective of highlighting the population at risk, and describing the clinical, radiological and histopathological features. Recommendations for the management of mucormycosis in the context of COVID-19 infection are also be discussed.

In December 2020, our group observed mucormycosis in some 

During the study period, the three tertiary hospitals admitted a total of 2567 diagnosed with COVID-19. Of them, a total of 47 (1.8%) subjects, who were diagnosed with mucormycosis and COVID-19, were included in this study. The majority were men (n = 35, 74.5%), and the mean age was 55 ± 12.8 years (Table 1) . A significant proportion of subjects had a background history of diabetes mellitus (n = 36, 76.6%) while 27 (57.4%) were on medications for hypertension. Of note, a background history of sinusitis was present only in 6 (12.7%) patients. Importantly, at the point of hospitalisation, the majority of subjects (n = 31, 66.0%) had not been vaccinated for COVID-19.

All subjects presented with fever, cough, rhinorrhoea, myalgia and breathlessness upon exertion or at rest. Based on the CT thorax severity score, majority (n = 43, 91.5%) had moderate-to-severe Table 2) .

Where laboratory investigations were available, the mean HbA1c was found to be 10.0 ± 2.1% (n = 29), mean D-dimer level was 305 ± 335.9 ng/ml (n = 23) (normal <250 ng/ml), mean C-reactive protein (CRP) level was 76.4 ± 55.6 mg/L (n = 24) (normal <10 mg/L), and mean ferritin level was 357.0 ± 280.3 ng/mL (n = 14) (normal 20-250 ng/mL). Interestingly, none of our patients had biochemical evidence of diabetic ketoacidosis.

The mean time interval between the diagnosis of COVID-19 and the appearance of symptoms suggestive of mucormycosis was 12.1 ± 4.6 days. All patients initially presented with nasal congestion with or without discharge consistent with sinusitis. The majority of patients with mucormycosis experienced a non-descript localised or generalised headache (n = 35, 74.5%). Other reported symptoms include diplopia, visual disturbances, facial weakness or numbness.

Features of ophthalmoplegia, partial third nerve palsy, proptosis and long-tract signs were also observed in a proportion of patients (Table 3 ). Imaging investigations revealed that almost all patients Table 3 ). Factors for not carrying out surgery were poor prognosis or death of the patients before the planned procedure. 

We report the clinical, radiological and histopathological features of mucormycosis in a series of COVID-19 patients. Poor glycaemic control, moderately severe pneumonia, mechanical ventilation and non-receipt of COVID-19 vaccine were the commonest predisposing factors for mucormycosis.

Mucormycosis is a potentially fatal infection which arises from the invasion of blood vessels by fungal elements leading to mycotic thrombosis, ischaemic infarction and ultimately necrosis of affective host tissues. 34 Globally, the incidence of mucormycosis has been described to range from 0.005 to 1.7 per million population, 35 whereas in India, the reported prevalence was 0.14 per 1000, approximately 80 times higher than that in developed countries, making it the country with the highest burden of mucormycosis. 36 Clinico-radiological findings in a patient (number 27 in our series) are shown in Figure 1 . The most common type of mucormycosis is rhinocerebro-orbital (44%-49%), followed by cutaneous (10%-19%) , pulmonary (10%-11%), disseminated (6%-11%) and gastrointestinal (2%-11%). 24 Diabetes, especially when uncontrolled, represents the single most common predisposing factor for mucormycosis in India, being reported in more than 50% of cases of mucormycosis. 46 SARS-CoV-2 virus has been found to impair cell-mediated immunity due to a decrease in CD4+ and CD8+ cell counts, increasing the vulnerability to fungal infections. 11 found to be significantly higher in patients with COVID-19 and secondary fungal infections (53%) as compared to those without (31%). 6 Despite early diagnosis and aggressive surgical and medical therapy, the prognosis for recovery from mucormycosis is generally poor. 39 We observed a similar pattern in our study. ARDS when they were treated with dexamethasone. 51 Although not supported by strong scientific data, vast majority of our patients received anti-viral therapy during the course of their treatment, which is in line with local management guidelines about the off-label use of these drugs in COVID-19 patients with moderate-to-severe disease requiring supplemental oxygen. 49 In our cohort of patients diagnosed with COVID-19 pneumonia and mucormycosis, about three-quarters had a pre-existing history of diabetes mellitus along with a poor glycaemia control at presentation.

This represents the pattern of the general population to some extent since India ranks second with respect to the prevalence of diabetes among adults aged 20-79 years. 52 Furthermore, the presence of diabetes among almost all our patients, who eventually succumbed to their disease, is consistent with previous studies reporting that diabetes as an independent risk factor for mucormycosis, especially when uncontrolled. 13, 24, 35, 53 Pathophysiologically, diabetes may cause quantitative and functional alterations in cell-mediated immunity such as chemotaxis and phagocytosis. 54 Other mechanisms that exacerbate the 'cytokine storm' include reduced natural killer cell activity, attenuated IFNγ response and an extended hyperinflammatory state. 54 In addition, endothelial dysfunction and vasoconstriction may result in tissue ischaemia and a procoagulant state. 54 The first step in the management of mucormycosis is to have a high index of clinical suspicion especially in those with COVID-19

who have diabetes mellitus, and who have received systemic corticosteroids. The mean duration between the diagnosis of COVID-19 and the appearance of mucormycosis in our study was 12.1 ± 4.6 days, which is consistent with a previous study. 11 However, symptoms of rhino-orbital mucormycosis may also develop as late as 3-42 days post-COVID-19 diagnosis, or those who have recovered from the infection. 14,53 Thus, a low threshold for investigation and imaging is critical to avoid the impending complications and higher mortality. 13 All of our subjects had presented with symptoms of sinusitis, and the extension beyond the paranasal sinuses occurred in nearly 79% of our subjects. These findings imply that physicians should examine the cranial nerves, assess vision, and evaluate for sinus tenderness regularly, especially for diabetic patients who received systemic corticosteroids. 14, 55 Any new symptoms should prompt further investigation for mucormycosis since eschar formation, the hallmark of mucormycosis, is often a late sign. Serial radiological investigations (CT and/or MRI) may help in assessing the extent and progression of the disease. 56 The definitive diagnosis of fungal infection can be easily made based on direct microscopy of nasal swab or surgical/ naso-endoscopic specimens with potassium hydroxide (KOH) mount and microbiological/histological confirmation. 38 The presence of broad, non-or pauci-septate fungal hyphae right angle branches, necrotising granulomatous inflammation and angio-invasion supports the diagnosis. 57 Serology tests are less likely to be helpful.

Interestingly, the raised ferritin levels in some of our patients may be indicative of an elevated level of free iron, which has been known to increase the susceptibility of infection to mucor but not to other pathogenic fungi, such as Candida or Aspergillus. 58 A multidisciplinary team approach involving an internist, intensivist, otolaryngologist, ophthalmologist, infectious diseases specialist, neurologist and/or neurosurgeon is often necessary. The mainstay of treatment are antifungals and surgical debridement of affected tissues. We propose a diagnostic and treatment algorithm of mucormycosis in patients with COVID-19 ( Figure 2 53 Lastly, being an observational study, there is no control group to evaluate reliable differences and association. 

None of the authors declare any competing interests associated with this manuscript. 

The study was approved by the Institutional Ethics Committee.

All patients or their legally acceptable relatives provided consent for using their data for academic and research purposes.

Not applicable. However, the data could be shared upon reasonable request to the corresponding author.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention

A novel coronavirus from patients with pneumonia in China

Listings of WHO's response to COVID-19

Coronovirus COVID-19 global cases

Rhino-orbital mucormycosis associated with COVID-19

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum

Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature

Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China

Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome

Mucormycosis with orbital compartment syndrome in a patient with COVID-19

Mucor in a viral land: a tale of two pathogens

A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis

The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis

Rhinocerebral Mucormycosis and COVID-19 pneumonia

Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19

When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis

Pulmonary aspergillosis and mucormycosis in a patient with COVID-19

A fatal case of rhizopus azygosporus pneumonia following COVID-19

Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19)

Sinoorbital mucormycosis in a COVID-19 patient: a case report

SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? a retrospective, multi-centric analysis

Fungal infections of oral cavity: diagnosis, management, and association with COVID-19

COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?

Title of the article: paranasal mucormycosis in COVID-19 patient

COVID-19 and orbital mucormycosis

COVID-19 and eye: a review of ophthalmic manifestations of COVID-19

Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report

COVID-19 and mucormycosis of the craniofacial skeleton: causal, contributory or coincidental?

A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19

Autopsy proven pulmonary mucormycosis due to rhizopus microsporus in a critically Ill COVID-19 patient with underlying hematological malignancy

Mucormycosis in a diabetic patient: a case report with an insight into its pathophysiology

The epidemiology and clinical manifestations of mucormycosis: a systematic review and metaanalysis of case reports

Mucormycosis: battle with the deadly enemy over a five-year period in India

Global epidemiology of mucormycosis

A multidisciplinary educational curriculum for the management of orbital compartment syndrome

Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis

Orbital exenteration in rhino-orbito-cerebral mucormycosis: a prospective analytical study with scoring system

Orbital mycoses in an adult subtropical population

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment

Invasive fungal diseases during COVID-19: we should be prepared

Creactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis

Ministry of Health and Family Welfare GoIAI-C-NTFJMG. Clinical guidance for management of adult COVID-19 patients

WHO. COVID-19 Clinical management: living guidance (WHO reference number

Dexamethasone in hospitalized patients with Covid-19

Federation. ID. Diabetes Atlas

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Diabetes, infection risk and COVID-19

Craniofacial pain in COVID-19 patients with diabetes mellitus: clinical and laboratory description of 21 cases

A case of successfully treated rhinocerebral mucormycosis: dental implications

Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment

All India ophthalmological society -oculoplastics association of India consensus statement on preferred practices in oculoplasty and lacrimal surgery during the COVID-19 pandemic

Mucormycosis and COVID-19: An epidemic within a pandemic in India